247 related articles for article (PubMed ID: 27272349)
1. Novel Gene Expression Signature Predictive of Clinical Recurrence After Radical Prostatectomy in Early Stage Prostate Cancer Patients.
Shahabi A; Lewinger JP; Ren J; April C; Sherrod AE; Hacia JG; Daneshmand S; Gill I; Pinski JK; Fan JB; Stern MC
Prostate; 2016 Oct; 76(14):1239-56. PubMed ID: 27272349
[TBL] [Abstract][Full Text] [Related]
2. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.
Geybels MS; Wright JL; Bibikova M; Klotzle B; Fan JB; Zhao S; Feng Z; Ostrander EA; Lin DW; Nelson PS; Stanford JL
Clin Epigenetics; 2016; 8():97. PubMed ID: 27651837
[TBL] [Abstract][Full Text] [Related]
4. Identification of a five gene signature to predict time to biochemical recurrence after radical prostatectomy.
Corradi JP; Cumarasamy CW; Staff I; Tortora J; Salner A; McLaughlin T; Wagner J
Prostate; 2021 Jul; 81(10):694-702. PubMed ID: 34002865
[TBL] [Abstract][Full Text] [Related]
5. Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy.
Sandeman K; Eineluoto JT; Pohjonen J; Erickson A; Kilpeläinen TP; Järvinen P; Santti H; Petas A; Matikainen M; Marjasuo S; Kenttämies A; Mirtti T; Rannikko A
PLoS One; 2020; 15(7):e0235779. PubMed ID: 32645056
[TBL] [Abstract][Full Text] [Related]
6. The New Prostate Cancer Grading System Does Not Improve Prediction of Clinical Recurrence After Radical Prostatectomy: Results of a Large, Two-Center Validation Study.
Dell'Oglio P; Karnes RJ; Gandaglia G; Fossati N; Stabile A; Moschini M; Cucchiara V; Zaffuto E; Karakiewicz PI; Suardi N; Montorsi F; Briganti A
Prostate; 2017 Feb; 77(3):263-273. PubMed ID: 27753114
[TBL] [Abstract][Full Text] [Related]
7. Gene expression signature of Gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort.
Jhun MA; Geybels MS; Wright JL; Kolb S; April C; Bibikova M; Ostrander EA; Fan JB; Feng Z; Stanford JL
Oncotarget; 2017 Jun; 8(26):43035-43047. PubMed ID: 28496006
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer.
Xu N; Chen HJ; Chen SH; Xue XY; Chen H; Zheng QS; Wei Y; Li XD; Huang JB; Cai H; Sun XL
Medicine (Baltimore); 2016 Jul; 95(29):e4326. PubMed ID: 27442684
[TBL] [Abstract][Full Text] [Related]
9. Genetic predisposition to early recurrence in clinically localized prostate cancer.
Borque Á; del Amo J; Esteban LM; Ars E; Hernández C; Planas J; Arruza A; Llarena R; Palou J; Herranz F; Raventós CX; Tejedor D; Artieda M; Simon L; Martínez A; Carceller E; Suárez M; Allué M; Sanz G; Morote J
BJU Int; 2013 Apr; 111(4):549-58. PubMed ID: 22759231
[TBL] [Abstract][Full Text] [Related]
10. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy.
Erho N; Crisan A; Vergara IA; Mitra AP; Ghadessi M; Buerki C; Bergstralh EJ; Kollmeyer T; Fink S; Haddad Z; Zimmermann B; Sierocinski T; Ballman KV; Triche TJ; Black PC; Karnes RJ; Klee G; Davicioni E; Jenkins RB
PLoS One; 2013; 8(6):e66855. PubMed ID: 23826159
[TBL] [Abstract][Full Text] [Related]
11. Validation of a 10-gene molecular signature for predicting biochemical recurrence and clinical metastasis in localized prostate cancer.
Abou-Ouf H; Alshalalfa M; Takhar M; Erho N; Donnelly B; Davicioni E; Karnes RJ; Bismar TA
J Cancer Res Clin Oncol; 2018 May; 144(5):883-891. PubMed ID: 29511883
[TBL] [Abstract][Full Text] [Related]
12. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study.
Lalonde E; Ishkanian AS; Sykes J; Fraser M; Ross-Adams H; Erho N; Dunning MJ; Halim S; Lamb AD; Moon NC; Zafarana G; Warren AY; Meng X; Thoms J; Grzadkowski MR; Berlin A; Have CL; Ramnarine VR; Yao CQ; Malloff CA; Lam LL; Xie H; Harding NJ; Mak DYF; Chu KC; Chong LC; Sendorek DH; P'ng C; Collins CC; Squire JA; Jurisica I; Cooper C; Eeles R; Pintilie M; Dal Pra A; Davicioni E; Lam WL; Milosevic M; Neal DE; van der Kwast T; Boutros PC; Bristow RG
Lancet Oncol; 2014 Dec; 15(13):1521-1532. PubMed ID: 25456371
[TBL] [Abstract][Full Text] [Related]
13. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.
Yokomizo A; Murai M; Baba S; Ogawa O; Tsukamoto T; Niwakawa M; Tobisu K; Kinukawa N; Naito S
BJU Int; 2006 Sep; 98(3):549-53. PubMed ID: 16925752
[TBL] [Abstract][Full Text] [Related]
14. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
[TBL] [Abstract][Full Text] [Related]
15. Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer.
Gandaglia G; Fossati N; Zaffuto E; Bandini M; Dell'Oglio P; Bravi CA; Fallara G; Pellegrino F; Nocera L; Karakiewicz PI; Tian Z; Freschi M; Montironi R; Montorsi F; Briganti A
Eur Urol; 2017 Oct; 72(4):632-640. PubMed ID: 28412062
[TBL] [Abstract][Full Text] [Related]
16. Validation of GEMCaP as a DNA Based Biomarker to Predict Prostate Cancer Recurrence after Radical Prostatectomy.
Nguyen HG; Welty C; Lindquist K; Ngo V; Gilbert E; Bengtsson H; Magi-Galluzzi C; Jean-Gilles J; Yao J; Cooperberg M; Messing E; Klein EA; Carroll PR; Paris PL
J Urol; 2018 Mar; 199(3):719-725. PubMed ID: 28941923
[TBL] [Abstract][Full Text] [Related]
17. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
18. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
19. External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer.
Roumiguié M; Beauval JB; Filleron T; Benoit T; Rischmann P; de la Taille A; Salomon L; Soulié M; Malavaud B; Ploussard G
BJU Int; 2014 Dec; 114(6b):E113-E119. PubMed ID: 24684584
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
Giesing M; Suchy B; Driesel G; Molitor D
BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
